US FDA seeks input on nanotechnology guidelines
This article was originally published in Scrip
Executive Summary
The US FDAwill gather public comments and data at a September 8th meeting to aid the development of guidelines for nanotechnology products. Last year an agency task force report recommended development of various guidance documents on the use of nanoscale materials (Scrip Online, July 26th, 2007). These included guidelines for sponsors on identifying the particle size for drugs and biologicals, and for submitting information on how nanoscale materials affect the manufacturing process. The meeting's primary purpose is to determine what factors the FDA should consider in providing guidance on the information and data needed to demonstrate safety and effectiveness of products containing nanoscale materials, and the circumstances under which a product's regulatory status might change owing to the presence or use of nanoscale materials.
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.
Preterm Birth Prevention Studies Need To Look Beyond Makena Endpoints, Experts Say
Gestational age and a binary, neonatal composite endpoint are insufficient to assess outcomes that are important to babies and families, clinicians and researchers say, suggesting development of continuous variables or scales with weighted components and a comparison of outcomes among newborns in gestational age ‘buckets.’